Immuneering (IMRX) will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104. Specifically, the company plans to present: Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer. Initial data from IMM-1-104 in combination with mFFX in first-line pancreatic cancer. Initial data from IMM-1-104 monotherapy in second-line pancreatic cancer.In addition, the company will provide initial PK, PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMRX:
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering granted FDA Fast Track designation for IMM-1-104
- Immuneering Corp. Reports Q3 Loss, Highlights Progress
- Immuneering reports Q3 EPS (49c), consensus (55c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
